Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13418MR)

This product GTTS-WQ13418MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Gastric Cancer research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ13418MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9276MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMMU-132
GTTS-WQ5740MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ8334MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HN-66000
GTTS-WQ5707MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ8945MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ15191MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TA-650
GTTS-WQ6707MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DS 1024
GTTS-WQ4409MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-663513
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW